menu
    • menu
    [{"orgOrder":0,"company":"ChemDiv","sponsor":"Orionis Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ORB-011","moa":"cDC1 dendritic cell","graph1":"Oncology","graph2":"Phase I","graph3":"ChemDiv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ChemDiv \/ Orionis Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"ChemDiv \/ Orionis Biosciences"},{"orgOrder":0,"company":"ChemDiv","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ChemDiv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ChemDiv \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ChemDiv \/ Undisclosed"},{"orgOrder":0,"company":"ChemDiv","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AV5124","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ChemDiv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"ChemDiv \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ChemDiv \/ Undisclosed"},{"orgOrder":0,"company":"ChemDiv","sponsor":"Mondego Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"ZE00-0388","moa":"PTPN2","graph1":"Oncology","graph2":"Preclinical","graph3":"ChemDiv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChemDiv \/ Mondego Bio","highestDevelopmentStatusID":"4","companyTruncated":"ChemDiv \/ Mondego Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by ChemDiv

    Menu

    ChemDiv

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ChemDiv

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            ChemDiv

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZE00-0388

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Mondego Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ChemDiv Extends Partnership with Mondego Bio on PTPN2 Immuno-Oncology Program

                            Details : The collaboration aims to advance ZE00-0388 in the treatment of cancer by targeting PTPN2.

                            Product Name : ZE00-0388

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 24, 2025

                            Lead Product(s) : ZE00-0388

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Mondego Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ChemDiv

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            ChemDiv

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORB-011

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Orionis Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChemDiv Marks Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase 1 Trials

                            Details : ORB-011 is a cutting-edge attenuated, cis-targeted interferon immunotherapy compound. It is under phase 1 clinical development for the treatment of patients with advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 03, 2024

                            Lead Product(s) : ORB-011

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Orionis Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ChemDiv

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            ChemDiv

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV5124

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChemDiv Helps Advance Viriom's Influenza Treatment to Successful Phase I Clinical Trials Completion

                            Details : AV5124 is an Influenza viral RNA processing inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of influenza.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 19, 2023

                            Lead Product(s) : AV5124

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ChemDiv

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            ChemDiv

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChemDiv Created Unique KATO TM Platform for Development of Innovative Drugs Against Coronavirus Infection

                            Details : Platform combines libraries of more than 120,000 unique potential antiviral molecules that targets various cellular proteins. Libraries cover highly important coronaviruses as well as HIV, HBV and Influenza.

                            Product Name : Avifavir

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 12, 2020

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth